Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific internal transaction rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs for a connected person.
Outlook, Risks, and Unusual Items
There is no management commentary, guidance, or outlook provided in this filing. The transaction was notified in accordance with Disclosure and Transparency Rule 3.1.4R (1)(c). No unusual items or contingencies affecting the company's broader operations are mentioned.
Investor Verification Points
- Transaction Date: The notional allocation increase occurred on October 14, 2011.
- Price per ADR: The transaction price was $43.64 per ADR.
- Parties Involved: The transaction involved Director Dr. M. M. Slaoui and Connected Person Dr. K. Slaoui.
- Volume: The number of ADRs allocated was 3.
- Plan Context: The transaction relates to the US Retirement Savings Plan, which is notionally held in GSK Ordinary share ADRs.